Isabel is Co-Fund Manager for Aviva Investors’ European Real Estate Long Income Fund (E-RELI Fund). She is responsible for supporting the Fund Manager in delivering the Fund’s strategy including progress of asset management and value-add initiatives, and sourcing and managing acquisitions for the Fund. Isabel is also part of the dedicated Real Estate Long Income Origination Team where her role is to source and create investment opportunities across a variety of assets in the UK and European markets.
Experience and qualifications
Prior to joining Aviva Investors, Isabel worked at PwC where she spent eight years with their real estate restructuring and corporate finance teams, advising on a range of debt and equity transactions in the UK and Europe.
Isabel holds a BSc (Hons) from Bristol University and an MA from Cass Business School. She is a qualified Chartered Surveyor.
You might also be interested in
Zero-COVID: China’s costly policy error
10 Aug. 2022
Beijing’s ideological battle to stamp out COVID-19 appears increasingly misguided as the rest of the world learns to live with the virus. But the impact of China’s approach will be felt far beyond its borders.
The AIQ Podcast: Taking stock of nature risk
15 Jul. 2022
The idea that human actions are bringing natural systems close to breakdown, threatening livelihoods and financial stability, is making asset managers think harder about nature risk and the environmental dependencies in investee companies.
Supply chains, painkillers and gene editing: ESG risks in pharma
29 Jun. 2022
Reflecting on ESG risks in the pharmaceutical industry, Sora Utzinger discusses supply chains and counterfeit medicines, access to painkillers, and the ethics of gene editing.
What does the data say? Where have the safe havens gone?
27 May 2022
In this month’s instalment of our visual series on topical themes, we look at how various asset classes are holding up in a turbulent year for financial markets.
Life force: Why nature matters
12 May 2022
Growing awareness that natural systems are stressed or even close to breakdown is prompting asset managers to look closely at nature-based risks and investee companies to understand their environmental impacts and dependencies.
Back to nature: Why we must act now on the biodiversity crisis
31 Mar. 2022
In an age of mass extinctions, policymakers, businesses and financial institutions are beginning to acknowledge the risks associated with biodiversity loss, along with the opportunities that arise from nature-positive solutions.
Now for the hard part…..The challenge of delivering net zero
29 Mar. 2022
More than one fifth of the world’s largest listed companies have committed to net-zero targets, but few have detailed roadmaps to get there. Mirza Baig considers the challenges for investors managing transition pathways.
Ukraine-Russia crisis: The implications for global equities
29 Mar. 2022
Our global equities team discuss the main direct and indirect consequences of the Ukraine-Russia crisis for stocks.
Politics, activists and ESG: The outlook for UK equities
10 Mar. 2022
We bring together members of our UK equities team to discuss the key opportunities and risks in the market.
China, inflation and politics: Three reasons for EM turbulence
24 Feb. 2022
Emerging market assets have underperformed developed market peers over the past decade. While this has led to valuation gaps, selectivity will be critical, argues David Nowakowski.
Where the wild things are: Why investors should care about natural capital
14 Dec. 2021
Finance must wake up to the risks associated with biodiversity loss and the opportunities that arise from nature-friendly solutions, argue Eugenie Mathieu, Julie Zhuang and Jonathan Toub.
Waste not, want not: An investor’s guide to the circular economy
10 Dec. 2021
Using the examples of electronics, food, autos and fashion, we explore the benefits of, and challenges to achieving, a more circular economy.
The future of pharma: Increased returns or the age of biotech?
8 Dec. 2021
After decades of low returns on research and development (R&D), the healthcare sector is producing a slew of innovations, from drugs to diagnostics. But with many coming from new entrants, will big pharmaceutical companies manage to keep up with the times?
The long decline: Why trend economic growth is set to go on falling
12 Nov. 2021
Trend rates of economic growth, which have been on the decline for decades in the world’s leading economies, look set to fall further. That will have big implications for governments, companies, households and investors, argues Stewart Robertson.
Regulatory shifts in China: A new fork in the road?
12 Oct. 2021
Investors in China should view recent interventions by the government in the context of its history and longer-term strategic ambitions, argues Amy Kam.
The AIQ Podcast: China's tech crackdown
21 Sep. 2021
China’s regulators are taking swift, radical action against tech companies they consider to be too big and powerful. How should foreign investors respond?